Cambridge BioMarketing, a health care marketing communications agency focused on orphan and specialty pharmaceuticals, said that Intercept Pharmaceuticals Inc. has named it the agency of record for the expected launch of a drug designed to treat patients with diseased livers.
Intercept’s lead product candidate is obeticholic acid, or OCA, a bile acid analog. According to the company’s website, OCA is initially being developed for primary biliary cirrhosis, or PBC.
The account, previously unassigned, was awarded based on the agency’s experience in rare diseases with unmet medical needs, Cambridge BioMarketing said. Billings were not disclosed.
Intercept has offices in New York and San Diego.